Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy

Lung Cancer ◽  
2009 ◽  
Vol 65 (3) ◽  
pp. 377-382 ◽  
Author(s):  
Hyun Woo Lee ◽  
Yong-Won Choi ◽  
Jae Ho Han ◽  
Jang Hee Kim ◽  
Jae Ho Jung ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Excision Repair ◽  
Complementation Group ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Doublet Chemotherapy ◽  
Group 1

scholarly journals Heterogeneity of excision repair cross-complementation group 1 gene expression in non-small-cell lung cancer patients

2014 ◽  
Vol 3 (1) ◽  
pp. 227-331 ◽  
Author(s):  
SERHEY SMIRNOV ◽  
ANASTASIYA PASHKEVICH ◽  
VALERIYA LIUNDYSHEVA ◽  
ANDREY BABENKO ◽  
RAISA SMOLYAKOVA
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Excision Repair ◽  
Complementation Group ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Group 1

Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non–Small-Cell Lung Cancer Treated With Carboplatin and Gemcitabine

2009 ◽  
Vol 27 (26) ◽  
pp. 4254-4259 ◽  
Author(s):  
Bente Holm ◽  
Anders Mellemgaard ◽  
Torsten Skov ◽  
Birgit Guldhammer Skov
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Median Survival ◽  
Cell Lung Cancer ◽  
Excision Repair ◽  
Complementation Group ◽  
Small Cell ◽  
Small Cell Lung ◽  
Survival Difference ◽  
Group 1

Purpose The excision repair cross-complementation group 1 (ERCC1) status was assessed in patients receiving carboplatin and gemcitabine for inoperable non–small-cell lung cancer (NSCLC). We analyzed the association between the ERCC1 status and the overall survival after the chemotherapy. Patients and Methods We retrospectively identified 163 patients with inoperable NSCLC and sufficient tumor tissue for ERCC1 analysis, who had received carboplatin and gemcitabine as first-line treatment. Immunohistochemistry was used to assess the expression of ERCC1. Results One hundred sixty-three patients were included. Seventy (42%) were ERCC1 positive. Patients treated with carboplatin and gemcitabine and having ERCC1-negative tumors had a significantly increased survival when compared to patients with ERCC1-positive tumors (median survival, 12.0 months v 8.2 months; P = .02). This difference was mainly seen in men, where those with ERCC1-negative tumors had a significantly increased survival compared to men with ERCC1-positive tumors (median survival, 11.8 months v 7.9 months; P = .005). Conversely, women who were ERCC1 negative did not have a survival advantage over ERCC1-positive women. Conclusion We confirmed previous reports that ERCC1 expression is predictive for outcome in patients treated with carboplatin and gemcitabine. Patients with ERCC1-negative tumors had an increased survival compared to patients with ERCC1-positive tumors and this difference was mainly attributable to a survival difference among men.

Sign in / Sign up

Export Citation Format

Share Document